Clinical trial
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
NCT01217931 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- January 19, 2011
- Completion date
- January 31, 2028
- Enrollment
- 180 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
kidney cancer